Back

ACTION

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: european organization for research and treatment of cancer-adjuvant chemotherapy in ovarian cancer trial

Date of Publication:

January 15, 2003

Pubmed Link:
https://pubmed.ncbi.nlm.nih.gov/12529344/
Hypothesis:

Does the addition of post-operative platinum-based chemotherapy improved OS for women with early stage epithelial ovarian cancer?

Control Arm(s):

TAH/BSO, staging (recommended - omentectomy, washings, biopsies, LN sampling)

Experimental Arm(s):

TAH/BSO, staging (recommended - omentectomy, washings, biopsies, LN sampling)at least 4 (but recommend 6) cycles of platinum-based chemotherapy (cisplain 75mg/m2, carboplatin 350mg/m2)

Primary End Point:

OS

Inclusion Criteria:

stage IA-B grade 2/3stage IC and IIAstage I-IIA clear cell

Exclusion Criteria:
Results:

surgery only (n=224) vs surgery/chemotherapy (n=224):33% of patients in each arm had recommended staging median f/u: 5.5 yrs5yr PFS: 68% vs 76% (SS)5yr OS: 78% vs 85% (NS)survival benefit of added chemotherapy mainly in women who did not have recommended staging

Conclusions:

OS was only improved by the addition of adjuvant chemotherapy in women with early stage ovarian cancer who did not undergo recommended staging. For the whole cohort, no OS benefit was seen, only a PFS benefit.

Reviewer:
Olga T Filippova